Proxy Votes Now

Home › Funds › Invesco › Invesco Health Care Fund

Invesco Health Care Fund (GGHCX) proxy voting record 2025-2026

Fund family: Invesco · Filed by AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) (CIK 826644) · SEC series S000000235

Share classes and tickers: GGHCX (C000000565), GGHYX (C000071224), GTHCX (C000000567), GTHIX (C000029647), GTHRX (C000265799)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 763 with, 19 against, 0 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 3 FOR, 18 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Invesco as a whole

The same two figures as Invesco’s manager page (413,145 ballot items across 270 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsInvescoItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)94.3%71894.5%357,245
Backed environmental and social shareholder proposals at US companiesn/a73.1%5,987

Where this fund voted differently from most Invesco funds

Each ballot item this fund voted is set against the votes of the other Invesco funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Invesco funds on 15 items (2.1% of the 714 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Invesco fundsMgmtResult
Edwards Lifesciences Corporation2026-05-07Advisory Vote to Approve Named Executive Officer CompensationAgainstFOR — 27 of 29 Invesco fundsAgainstApproved, 89.3% support
Medpace Holdings, Inc.2026-05-15Shareholder Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting.AgainstFOR — 13 of 13 Invesco fundsForFailed (calculated), 34.1% support
Globus Medical, Inc.2026-06-03Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. PfeilWithholdFOR — 13 of 13 Invesco fundsAgainstElected, 91.3% support
Quest Diagnostics Incorporated2026-05-20Shareholder Stockholder proposal regarding an independent board chairman, if properly presented at the Annual Meeting.AgainstFOR — 19 of 20 Invesco fundsForNot approved, 25.6% support
Vertex Pharmaceuticals Incorporated2026-05-13Shareholder Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.AgainstFOR — 22 of 24 Invesco fundsForApproved, 57.0% support
Globus Medical, Inc.2026-06-03Approval, on a non-binding, advisory basis, of the 2025 compensation of the company's named executive officers (the "Say-on-Pay" Vote).AgainstFOR — 17 of 18 Invesco fundsAgainstApproved, 98.4% support
IDEXX Laboratories, Inc.2026-05-12Shareholder Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six).AgainstFOR — 27 of 31 Invesco fundsFor—
Ligand Pharmaceuticals Incorporated2026-06-05Approval, on an advisory basis, of the compensation of the named executive officersAgainstFOR — 15 of 17 Invesco fundsAgainstApproved, 94.2% support
AbbVie Inc.2026-05-08Shareholder Stockholder Proposal - to Adopt a Policy to Require an Independent ChairAgainstFOR — 30 of 39 Invesco fundsForNot approved, 39.6% support
Mettler-Toledo International Inc.2026-05-07Advisory Vote to Approve Executive CompensationAgainstFOR — 22 of 28 Invesco fundsAgainstPassed (calculated), 87.9% support
Medpace Holdings, Inc.2026-05-15To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting.AgainstFOR — 17 of 21 Invesco fundsAgainst—
Protagonist Therapeutics, Inc.2026-06-17To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.AgainstFOR — 14 of 17 Invesco fundsAgainstApproved, 94.4% support
CVS Health Corporation2026-05-14Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.AgainstFOR — 29 of 41 Invesco fundsFor—
Boston Scientific Corporation2026-04-30Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."ForAGAINST — 21 of 32 Invesco fundsAgainstNot approved, 42.8% support
Alnylam Pharmaceuticals, Inc.2026-05-20To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.AgainstFOR — 17 of 29 Invesco fundsAgainst—

Download all 15 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 82.2% of this fund’s 782 such votes could be given a sector; the other 139 (17.8%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care580183.1%
Industrials3100.0%
Consumer Staples1715.9%
Real Estate1100.0%
Technology400.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5060
Audit-related800
Say-on-Pay710
Corporate Governance5212
Compensation470
Capital Structure230
Other Social Issues54
Shareholder Rights and Defenses40
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$162M102
Johnson & JohnsonApril 23, 2026$74M151
AbbVie Inc.May 8, 2026$73M81
Cencora, Inc.March 5, 2026$58M130
Gilead Sciences, Inc.April 30, 2026$56M153
argenx SEMay 6, 2026$50M120
argenx SENovember 18, 2025$50M10
McKesson CorporationJuly 30, 2025$39M140

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposalAgainstFor
April 23, 2026HCA Healthcare, Inc.Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor

Funds that vote the same way

These funds reported the same votes as Invesco Health Care Fund in the latest season, so they share this page:

Search this fund’s votes by company

791 ballot items at 78 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Invesco Health Care Fund (GGHCX) voted at 78 shareholder meetings of 77 companies, on 791 ballot items in all. Where management made a recommendation, the fund followed it on 97.6% of the items and voted against it 19 times. Its most frequent area of disagreement was corporate governance (12 of its votes against management). It voted on 21 shareholder proposals. It voted FOR the board's own proposals about as often as Invesco's funds as a whole (94.3% against 94.5%). It voted differently from most Invesco funds on 15 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Invesco’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.